Showing results (231-240 of 261) with videos related to
Sort By:
Pageof 27
American Heart Journal|February 23, 2020
Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapibJean-Claude Tardif, Marie-Pierre Dubé, Marc A Pfeffer, et al.Plos One|December 23, 2014
Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkersBenoit J Arsenault, Philip Barter, David A DeMicco, et al.Journal of the American College of Cardiology|December 28, 2010
Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkersBenoit J Arsenault, Philip Barter, David A DeMicco, et al.The American Journal of Cardiology|August 8, 2009
Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery diseaseOle Faergeman, Ingar Holme, Rana Fayyad, et al.Elife|January 23, 2026
HIV-specific CD8+ T-cell proliferative response 24 weeks after early antiretroviral therapy initiation is associated with the subsequent reduction in the viral reservoirPien Margien van Paassen, Alexander O Pasternak, Dita C Bolluyt, et al.Journal of Clinical Lipidology|November 7, 2017
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular riskBenoit J Arsenault, Francine Petrides, Fatiha Tabet, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 19, 2024
Genetic testing in a national cohort of adults with chronic kidney disease of unknown originAmber de Haan, Mark Eijgelsheim, Liffert Vogt, et al.Circulation. Genomic and Precision Medicine|April 2, 2021
Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular MedicineDavid Rhainds, Chris J Packard, Mathieu R Brodeur, et al.JAMA|November 19, 2002
Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trialDavid D Waters, Edwin L Alderman, Judith Hsia, et al.The New England Journal of Medicine|March 24, 2006
Effect of ACAT inhibition on the progression of coronary atherosclerosisSteven E Nissen, E Murat Tuzcu, H Bryan Brewer, et al.Pageof 27